Literature DB >> 29926189

The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer.

Hiroshi Sawayama1, Masaaki Iwatsuki1, Daisuke Kuroda1, Tasuku Toihata1, Tomoyuki Uchihara1, Yuki Koga1, Taisuke Yagi1, Yuki Kiyozumi1, Tsugio Eto1, Yukiharu Hiyoshi1, Takatsugu Ishimoto1, Yoshifumi Baba1, Yuji Miyamoto1, Naoya Yoshida1, Hideo Baba2.   

Abstract

PURPOSE: This study investigated the predictors associated with early recurrence (i.e. within 12 months) after curative gastrectomy for gastric cancer (GC).
METHODS: We evaluated the clinicopathological factors in 429 patients who underwent curative gastrectomy for GC without preoperative chemotherapy and analyzed these factors' associations with early recurrence.
RESULTS: Of 429 patients, 57 experienced recurrences, which were associated with gender, diameter, depth of invasion, lymph node (LN) metastasis, the LN ratio (LNr; LNs with metastasis/dissected LNs), lymphatic invasion, vascular invasion, carbohydrate antigen 19-9 (CA19-9) levels, C-reactive protein levels and the neutrophil/lymphocyte ratio. Twenty-one patients (36.8%) recurred within 12 months. Early recurrence was associated with a high LNr (P = 0.0020) and high CA19-9 levels (P = 0.0415). The other factors were not significantly associated with early recurrence. The 12-month recurrence rate was 33.9% in patients with a high LNr and 1.9% in those with a low LNr and 20.3% in patients with high CA19-9 levels and 3.5% in those with low CA19-9 levels. The 12-month recurrence rate was 62.5% in patients with a high LNr and high CA19-9 levels, 18.4% in those with a high LNr or high-CA19-9 levels, and 1.4% in those with a low LNr and low CA19-9 levels.
CONCLUSION: LNr ≥ 0.15 and CA19-9 ≥ 37 U/ml were effective surrogate markers for predicting early recurrence.

Entities:  

Keywords:  CA19-9; Early recurrence; Gastric cancer; Lymph node ratio

Mesh:

Substances:

Year:  2018        PMID: 29926189     DOI: 10.1007/s00595-018-1684-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  29 in total

1.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

2.  Correlation between lymph node count and survival and a reappraisal of lymph node ratio as a predictor of survival in gastric cancer: A multi-institutional cohort study.

Authors:  J H Lee; J-W Kang; B-H Nam; G S Cho; W J Hyung; M C Kim; H-J Lee; K W Ryu; S W Ryu; D W Shin; C-Y Kim
Journal:  Eur J Surg Oncol       Date:  2016-09-30       Impact factor: 4.424

3.  Prognostic significance of lymphovascular invasion in node-negative gastric cancer.

Authors:  Ju-Hee Lee; Min Gyu Kim; Min-Sung Jung; Sung Joon Kwon
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

4.  The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification.

Authors:  Y Kodera; Y Yamamura; Y Shimizu; A Torii; T Hirai; K Yasui; T Morimoto; T Kato; T Kito
Journal:  J Am Coll Surg       Date:  1998-12       Impact factor: 6.113

5.  The evaluation of metastatic lymph node ratio staging system in gastric cancer.

Authors:  Yanbing Zhou; Jizhun Zhang; Shougen Cao; Yu Li
Journal:  Gastric Cancer       Date:  2012-09-04       Impact factor: 7.370

6.  Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer.

Authors:  X Jiang; N Hiki; S Nunobe; K Kumagai; T Kubota; S Aikou; T Sano; T Yamaguchi
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

7.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

8.  Clinical significance of accurate identification of lymph node status in distant metastatic gastric cancer.

Authors:  Rui Zhou; Zhenzhen Wu; Jingwen Zhang; Hongqiang Wang; Yuqi Su; Na Huang; Min Shi; Jianping Bin; Yulin Liao; Wangjun Liao
Journal:  Oncotarget       Date:  2016-01-05

Review 9.  Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis.

Authors:  Yong-xi Song; Xuan-zhang Huang; Peng Gao; Jing-xu Sun; Xiao-wan Chen; Yu-chong Yang; Cong Zhang; Hong-peng Liu; Hong-chi Wang; Zhen-ning Wang
Journal:  Dis Markers       Date:  2015-10-21       Impact factor: 3.434

10.  Japanese gastric cancer treatment guidelines 2014 (ver. 4).

Authors: 
Journal:  Gastric Cancer       Date:  2016-06-24       Impact factor: 7.370

View more
  4 in total

Review 1.  Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy.

Authors:  Umme Hani; Riyaz Ali M Osmani; Sabina Yasmin; B H Jaswanth Gowda; Hissana Ather; Mohammad Yousuf Ansari; Ayesha Siddiqua; Mohammed Ghazwani; Adel Al Fatease; Ali H Alamri; Mohamed Rahamathulla; M Yasmin Begum; Shadma Wahab
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

2.  Reappraise role of lymph node status in patterns of recurrence following curative resection of gastric adenocarcinoma.

Authors:  Yihui Tang; Jianxian Lin; Junpeng Lin; Jiabin Wang; Jun Lu; Qiyue Chen; Longlong Cao; Mi Lin; Ruhong Tu; Changming Huang; Ping Li; Chaohui Zheng; Jianwei Xie
Journal:  Chin J Cancer Res       Date:  2021-06-30       Impact factor: 5.087

Review 3.  Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.

Authors:  Julita Machlowska; Jacek Baj; Monika Sitarz; Ryszard Maciejewski; Robert Sitarz
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

4.  Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: Based on a retrospective and observational study of follow-up within 3 years of 843 patients.

Authors:  Yifan Li; Haoliang Zhao
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.